Edition:
United States

Perrigo Company PLC (PRGO.N)

PRGO.N on New York Stock Exchange

68.43USD
22 Mar 2017
Change (% chg)

$0.29 (+0.43%)
Prev Close
$68.14
Open
$68.06
Day's High
$68.75
Day's Low
$67.36
Volume
341,672
Avg. Vol
452,313
52-wk High
$133.93
52-wk Low
$67.14

PRGO.N

Chart for PRGO.N

About

Perrigo Company plc (Perrigo), formerly Perrigo Company Limited, is an over-the-counter (OTC) consumer goods and specialty pharmaceutical company. The Company's segments include Consumer Healthcare (CHC), Branded Consumer Healthcare (BCH), Prescription Pharmaceuticals (Rx), Specialty Sciences and Other. It manufactures OTC... (more)

Overall

Beta: 0.70
Market Cap(Mil.): $9,811.11
Shares Outstanding(Mil.): 143.37
Dividend: 0.16
Yield (%): 0.94

Financials

  PRGO.N Industry Sector
P/E (TTM): -- 29.30 30.07
EPS (TTM): -10.47 -- --
ROI: -8.85 13.52 13.05
ROE: -15.49 14.43 14.20

BRIEF-Perrigo announced first-to-market launch of OTC store brand equivalent to women's Rogaine foam

* Perrigo Company Plc- announced first-to-market launch of over--counter store brand equivalent to women's Rogaine foam Source text for Eikon: Further company coverage:

Mar 08 2017

BRIEF-Perrigo says in process of identifying certain deferred tax assets, other related effects at Omega Pharma Invest N.V

* Perrigo Company Plc - in process of identifying certain deferred tax assets and other related effects at Omega Pharma Invest N.V.

Mar 07 2017

BRIEF-Perrigo announces FDA final approval for the generic version of Axiron topical solution

* Perrigo announces FDA final approval for the generic version of Axiron topical solution, 30 mg/1.5 ml Source text for Eikon: Further company coverage:

Mar 01 2017

BRIEF-Perrigo Company expects to reduce its workforce by about 750 employees

* Perrigo Company Plc - company expects to reduce its global workforce by approximately 750 employees

Feb 27 2017

BRIEF-Perrigo signs agreement to divest tysabri royalty stream for up to $2.85 billion

* Perrigo signs agreement to divest tysabri® royalty stream for up to $2.85 billion

Feb 27 2017

BRIEF-Perrigo Company Plc files for non-timely 10-Q

* Perrigo Company Plc - Is in the process of identifying certain deferred tax assets and other related effects at Omega Pharma Invest N.V.

Feb 27 2017

BRIEF-Perrigo says Ron Winowiecki appointed acting CFO

* Is conducting a thorough search process to identify a permanent Chief Financial Officer, which includes Mr. Winowiecki as a key candidate

Feb 27 2017

BRIEF-Perrigo sets quarterly dividend of $0.16 per share

* Sets quarterly dividend of $0.16 per share Source text for Eikon: Further company coverage:

Feb 21 2017

BRIEF-Perrigo announces FDA final approval for hydrocodone bitartrate and homatropine methylbromide oral solution

* Perrigo announces FDA final approval for hydrocodone bitartrate and homatropine methylbromide oral solution Source text for Eikon: Further company coverage:

Feb 17 2017

Perrigo adds three directors in deal with activist Starboard

Drugmaker Perrigo Co Plc struck a deal on Tuesday with Starboard Value LP, agreeing to add three directors to the board as the activist hedge fund ramps up pressure on the company.

Feb 08 2017

More From Around the Web

Earnings vs. Estimates